The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion. Boston Scientific Lowers FY EPS Outlook, Raises Adjusted EPS The ...

Boston Scientific (NYSE: BSX ... while Cardiovascular sales increased 25% from the same period a year ago. Endoscopy (7.8% growth), Urology (10.3%) and Neuromodulation (17%) drove MedSurg.

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Investing.com -- Boston Scientific (NYSE:BSX ... also above the $4.04 billion estimated by analysts. Endoscopy net sales were $678 million, a 7.8% year-over-year increase, slightly above the ...

The Farapulse Farawave catheter and Faraview software. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + announced today that it received FDA approval for its navigation ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...